European Society of Cardiology 2018

The 2018 congress of the European Society of Cardiology (ESC) recently concluded and has re-affirmed the exceptional status of this globe-spanning scientific endeavour. Society sources report that over five days, delegates from more than 150 countries presented, discussed or attended 4,500 abstracts in 500 expert sessions covering 400 cardiology topics. A total of 92 late-breaking science studies were presented including 17 Late Breaking Clinical Trials, six Clinical Trial Updates, and 20 Registries: these are extraordinary numbers.

Exceptional also is the calibre of the materials now being brought into the public domain. In the arena of acute heart failure the VERDICT trial produced the perhaps surprising but undoubtedly important finding that very early diagnosis and treatment in patients with non-ST segment elevation acute coronary syndrome was not superior to a strategy of assessment deferral: postponing invasive examination and treatment for up to 72 hours appears to be successful as a very early approach.

In parallel with these mainstream activities, the practical tutorials lectures were a great success, with high rates of attendance. In three full days, a faculty of 17 acknowledged experts dealt purposefully and informatively with major themes relating to the use of inodilators, particularly levosimendan, in acute and advanced heart failure. All the presentations, including the Q&A sessions which followed all lectures, were recorded and may be viewed freely at

View the ESC 2018 presentations in the Acute and Advanced Knowledge Centre.


Publications (22)
  • ESC 2017 in Barcelona

    Professor Gerhard Pölzl discusses the European Society of Cardiology annual meeting 2017, where several sessions were held on the use of levosimendan in heart failure.


    Professor Gerhard Pölzl highlights the significance of the FIGHT, PERSIST and LEVOREP trials which investigate levosimendan as a treatment for heart failure.

  • LEODOR trial - recent advances

    There have been some recent achievements in the LEODOR trial including a new website to facilitate administration and communication and submission of a formal study protocol synopsis to the European Journal of Heart Failure.

  • Levosimendan roars ahead as LION-HEART results published

    Professor Gerhard Pölzl reports primary results from the LION-HEART study in the management of advanced heart failure where among secondary endpoints, patients treated with levosimendan experienced a reduction in the rate of HF-related hospitalisation compared with placebo.

  • What does the Advanced Heart Failure patient want?

    Professor Cynthia M Dougherty and colleagues outline an array of options for the treatment of advanced heart failure (HF) that create – quite reasonably – the impression that we are in a golden age of therapeutic possibilities for this difficult condition.

  • Recent literature

    Explore the April 2019 blog from Professor Gerhard Pölz focuses on some of the recent literature he has read.

Login/ Register Maximise Minimise